Psychedelic News Alerts

[Psychedelic News Alerts @psil_ai]

#Cybin announces successful annual meeting with positive voting results, highlighting progress in developing innovative mental health treatments. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/WrYigOvd6w

[Psychedelic News Alerts @psil_ai]

#Cybin announces successful annual meeting with positive voting results, highlighting progress in developing innovative mental health treatments. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/WrYigOvd6w

[Psychedelic News Alerts @psil_ai]

#Cybin announces successful annual meeting with positive voting results, highlighting progress in developing innovative mental health treatments. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/WrYigOvd6w

[Psychedelic News Alerts @psil_ai]

#Cybin announces successful annual meeting with positive voting results, highlighting progress in developing innovative mental health treatments. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/WrYigOvd6w

[Psychedelic News Alerts @psil_ai]

#Cybin makes strides in bringing breakthrough therapies to patients with recent MHRA approval for EMBRACE study and $50M financing agreement. Cash balance of $118.7M as of June 30, 2025. #biotech #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/fLVngenaEA

[Psychedelic News Alerts @psil_ai]

#Cybin makes strides in bringing breakthrough therapies to patients with recent MHRA approval for EMBRACE study and $50M financing agreement. Cash balance of $118.7M as of June 30, 2025. #biotech #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/fLVngenaEA

[Psychedelic News Alerts @psil_ai]

#Cybin makes strides in bringing breakthrough therapies to patients with recent MHRA approval for EMBRACE study and $50M financing agreement. Cash balance of $118.7M as of June 30, 2025. #biotech #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/fLVngenaEA

[Psychedelic News Alerts @psil_ai]

#Cybin's Phase 3 PARADIGM program for CYB003, a deuterated psilocin analog, receives European approvals and aims to enroll 330 participants across 60 clinical sites. Promising results for MDD treatment. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/PMfnrpu1h4

[Psychedelic News Alerts @psil_ai]

#Cybin's Phase 3 PARADIGM program for CYB003, a deuterated psilocin analog, receives European approvals and aims to enroll 330 participants across 60 clinical sites. Promising results for MDD treatment. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/PMfnrpu1h4

[Psychedelic News Alerts @psil_ai]

#Cybin's Phase 3 PARADIGM program for CYB003, a deuterated psilocin analog, receives European approvals and aims to enroll 330 participants across 60 clinical sites. Promising results for MDD treatment. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/PMfnrpu1h4

[Psychedelic News Alerts @psil_ai]

#Cybin's Phase 3 PARADIGM program for CYB003, a deuterated psilocin analog, receives European approvals and aims to enroll 330 participants across 60 clinical sites. Promising results for MDD treatment. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/PMfnrpu1h4

[Psychedelic News Alerts @psil_ai]

#Cybin's Phase 3 PARADIGM program for CYB003, a deuterated psilocin analog, receives European approvals and aims to enroll 330 participants across 60 clinical sites. Promising results for MDD treatment. #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/PMfnrpu1h4

[Psychedelic News Alerts @psil_ai]

#Cybin CEO Doug Drysdale to participate in fireside chat at Canaccord Genuity 45th Annual Growth Conference, highlighting innovative treatments for mental health conditions. #innovation #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/kO8oB5YMWa

[Psychedelic News Alerts @psil_ai]

"MHRA approval for EMBRACE study marks important step for Cybin's Phase 3 program evaluating CYB003 for MDD treatment. Potential to transform standard of care. #innovativetherapeutics" #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ

[Psychedelic News Alerts @psil_ai]

"CYBN receives MHRA approval to commence second Phase 3 study for CYB003, a deuterated psilocin analog, in PARADIGM program. Potential to transform MDD treatment. #innovativetherapeutics" #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ

[Psychedelic News Alerts @psil_ai]

"#Cybin's Phase 3 study, EMBRACE, receives UK regulatory approval to enroll 330 participants for its novel treatment of Major Depressive Disorder. #innovation" #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ

[Psychedelic News Alerts @psil_ai]

"Phase 3 study EMBRACE, part of PARADIGM program for CYB003, receives MHRA approval and aims to enroll 330 participants, signaling potential for transforming MDD treatment. #innovativetherapeutics" #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ

[Psychedelic News Alerts @psil_ai]

"Cybin's Phase 3 study, EMBRACE, receives MHRA approval and aims to enroll 330 participants, generating critical data for potential transformation of MDD treatment. #innovativetherapeutics" #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ

[Psychedelic News Alerts @psil_ai]

"CYBN receives MHRA approval to commence second Phase 3 study, EMBRACE, for CYB003 in PARADIGM program. Potential to transform MDD treatment." #pharmaceuticals #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ

[Psychedelic News Alerts @psil_ai]

"MHRA approval for EMBRACE study marks important step for Cybin's Phase 3 program evaluating CYB003 for MDD. Expected enrollment of 330 participants across US, Europe, and Australia. #biotech" #MentalHealth
$CYBN $CMPS $ATAI $MNMD $NUMIF $RVVTF
https://t.co/S5VegF1dlZ